Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MK-3402 by Merck for Gram-Negative Bacterial Infections: Likelihood of Approval
MK-3402 is under clinical development by Merck and currently in Phase I for Gram-Negative Bacterial Infections. According to GlobalData, Phase...